All other COVID-19 tests in use have received emergency use authorizations, meaning they would not be eligible to be used once COVID-19 is no longer declared a public health emergency.
The test is made by BioFire Diagnostics, a Salt Lake City-based diagnostics company. It is a nasal swab test used to detect multiple respiratory viruses, including COVID-19.
The test is approved to test only symptomatic people suspected of having COVID-19 or another respiratory tract infection.
“While this is the first marketing authorization for a diagnostic test using a traditional premarket review process, we do not expect this to be the last, and look forward to working with developers of medical products to move their products through our traditional review pathways,” acting FDA Commissioner Janet Woodcock said in a news release.
Read the FDA’s full news release here.
More articles on supply chain:
FDA warns of false positives from Roche’s combo flu, COVID-19 test
Mississippi hospital still faces price-gouging, PPE shortages, supply chain director says
Cardinal Health to sell Cordis medical device business for $1B
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
